PolyPid Ltd. Ordinary Shares (PYPD)

FairStock Score: 31/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am looking for durable businesses with honest assets and owner earnings, but PolyPid is a clinical-stage biotech, so the usual moat test does not apply. Its lead candidate, D-PLEX100, is in a pivotal Phase 3 confirmatory trial for preventing surgical-site infections in abdominal colorectal surgery, using its PLEX polymer-lipid encapsulation matrix. That is a real unmet need, but there is no marketed product and no revenue growth figure provided. The FairStock score is 31/100. At the 2026-10-13 close of $4.88, the FairStock-calculated P/E is -3.73 and P/B is 18.07, so there are no earnings and the price is high versus book value. ROE is -243.59% and ROCE is -74.63%, meaning capital is being consumed at a severe rate. Debt/equity is only 0.29, but the Altman Z-score is -23.48 and the Piotroski F-score is 2/9, both warning of deep financial weakness. The Lynch category is none because only 0 years of filed results exist, while three are needed. Profit growth is not a meaningful guide here; the future depends on trial data, regulatory approval, and cash runway. The 52-week range of $3.10 to $5.73 and beta of 1.42 suggest a volatile, binary situation. Graham would demand a margin of safety, but here the $89.9M market cap is essentially a bet on clinical success, not a proven business with defensible earnings. I would treat it as speculative, not investment-grade.

In plain English: PolyPid is a small biotech with 69 employees developing a treatment to prevent infections after surgery. It has no marketed product yet, so it loses money and its financial signs look weak. At $4.88, the price looks expensive compared with its assets and earnings because there are no earnings, so it trades mostly on hopes for its lead trial.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer